rhIL-7, CF (5 ug)

rhIL-7, CF (5 ug)

分享
品牌: R&D Systems
pdf 下载产品说明书
pdf 下载SDS
用小程序,查商品更便捷
收藏
对比对比
咨询咨询
    产品介绍
    产品信息

    Scientific Data

    SEC-MALS View Larger

    Recombinant Human IL-7 Protein (Catalog # 207-IL) has a molecular weight (MW) of 16.0 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer.

    Carrier Free

    What does CF mean?

    CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

    What formulation is right for me?

    In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

    207-IL

    FormulationLyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
    ReconstitutionReconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
    ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
    Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

    207-IL/CF

    FormulationLyophilized from a 0.2 μm filtered solution in PBS.
    ReconstitutionReconstitute 5 μg vials at 50 μg/mL in sterile PBS. Reconstitute 10 μg or larger vials at 100 μg/mL in sterile PBS.
    ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
    Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

    Recombinant Human IL-7 Protein Summary

    Product Specifications

    Purity
    >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
    Endotoxin Level
    <0.01 EU per 1 μg of the protein by the LAL method.
    Activity
    Measured in a cell proliferation assay using PHA-activated human peripheral blood lymphocytes (PBL). Yokota, T. et al. (1986) Proc. Natl. Acad. Sci. USA 83:5894. The ED50 for this effect is 0.1-0.5 ng/mL.
    Source
    E. coli-derived human IL-7 protein
    Asp26-His177, with an N-terminal Met
    Accession #
    N-terminal Sequence
    Analysis
    Met
    Predicted Molecular Mass
    17 kDa
    背景
    背景

    Background: IL-7

    IL-7 (interleukin-7) is a 25 kDa cytokine of the hemopoietin family that plays important roles in lymphocyte differentiation, proliferation, and survival (1-4). Human IL‑7 cDNA encodes 177 amino acids (aa) that include a 25 aa signal peptide (3). Human IL-7 shares approximately 60-63% aa sequence identity with mouse, rat, canine and feline IL-7, and 72-76% with equine, bovine, ovine, and porcine IL-7. Human and mouse IL-7 exhibit cross-species activity (2, 3).

    IL-7 is produced by a wide variety of cells in primary and secondary lymphoid tissues, including stromal epithelial cells of the thymus, bone marrow, and intestines (1, 2, 5). Circulating IL-7 is limiting in healthy animals, but increases during lymphopenia (1, 6). IL-7 signals through a complex of the IL-7 Receptor alpha subunit (IL-7 R alpha, also known as CD127) with the common gamma chain ( gamma c) (1). The gamma c is also a subunit of the receptors for IL-2, -4, -9, -15, and -21 (1).

    IL-7 R alpha is expressed on double negative (CD4-CD8-) and single positive (CD4+ or CD8+) naïve and memory T cells, but undergoes IL-7-mediated down‑regulation and shedding during antigen-driven T cell proliferation, and is absent on regulatory T cells (1, 2, 6-11). IL-7 contributes to the maintenance of all naïve and memory T cells, mainly by promoting expression of the anti-apoptotic protein Bcl-2 (9-11). It is required for optimal T cell-dendritic cell interaction (6). IL-7 is expressed early in B cell development prior to the appearance of surface IgM (1, 5, 9). In mouse, IL-7 activation of IL-7 R alpha is critical for both T cell and B cell lineage development, while in humans, it is required for T cell but not for B cell development (4, 9, 12, 13). However, IL-7 functions in both mouse and human pro-B cells to suppress premature Ig light chain recombination during proliferative growth (14, 15).

    Like other common gamma-chain cytokines like IL-2 and IL-15, IL-7 and its receptor, IL-7R, have been used in a variety of immunotherapy applications, often in fluid tumors and in some instances of solid tumor models (16). Sometimes use of recombinant IL-7 is preferential as current studies and early clinical trials of cancer have found less severe toxicity or side effects upon treatment with IL-7 in comparison to IL-15 or IL-2 (16).

    In CAR-T cell therapies, enhanced expression and secretion of human IL-7 and CCL19 have enhanced the ability of T cells to expand and migrate in vitro (17). Engineered CAR T cells expressing IL-7 or a constitutively active IL-7R results in increased efficacy of CAR T anti-tumor effects (16, 18). IL-7 is also frequently used in combination with IL-15 as a supplement in cell culture of CAR T cells to support their expansion (19). Additionally, IL-7/IL-15 in the presence of cord blood-derived T cells helps to maintain their early differentiation state (20).

    Monoclonal antibodies against IL-7R or small molecule inhibitors against the IL-7R signaling pathway are commonly used in circumstances of autoimmune diseases to delay disease progression (16).  Also due to its ability to stimulate both adaptive and innate immune cells, treatment with IL-7 has shown improved survival in patients with sepsis who are at risk of deadly secondary infections (21), providing evidence for IL-7 applications beyond cancer immunotherapy.

    References
    1. Sasson, S.C. et al. (2006) Curr. Drug Targets 7:1571.
    2. Barata, J.T. et al. (2006) Exp. Hematol. 34:1133.
    3. Goodwin, R.G. et al. (1990) Proc. Natl. Acad. Sci. USA 86:302.
    4. Namen, A.E. et al. (1988) Nature 333:571.
    5. Shalapour, S. et al. (2012) PLoS ONE 7: e31939.
    6. Saini, M. et al. (2009) Blood 113:5793.
    7. Park, J.H. et al. (2004) Immunity 21:289.
    8. Vranjkovic, A. et al. (2007) Int. Immunol. 19:1329.
    9. Sudo, T. et al. (1993) Proc. Natl. Acad. Sci. 90:9125.
    10. Seddon, B. et al. (2003) Nat. Immunol. 4:680.
    11. Schluns, K.S. et al. (2000) Nat. Immunol. 5:426.
    12. Peschon, J.J. et al. (1994) J. Exp. Med. 180:1955.
    13. Pribyl, J.A. and T.W. LeBien (1996) Proc. Natl. Acad. Sci. 93:10348.
    14. Johnson, K. et al. (2012) J. Immunol. 188:6084.
    15. Nodland, S.E. et al. (2011) Blood 118:2116.
    16. Wang, C. et al. (2022) Int. J. Mol. Sci. 23(18).
    17. Pang, N. et al. (2021) J Hematol Oncol. 14(118).
    18. Li, L. et al. (2022) Scientific Reports. 12(12506).
    19. Xu, Y. et al. (2014) Blood. 123(24): 3750-3759.
    20. Marton, C. et al. (2022) Cancer Gene Ther. 29(7).
    21. Winer, H. et al. (2022) Cytokine. 160(156049).
    Long Name
    Interleukin 7
    Entrez Gene IDs
    3574 (Human); 16196 (Mouse); 25647 (Rat)
    Alternate Names
    IL7; IL-7; IL-7interleukin-7; interleukin 7; Lymphopoietin-1; PBGF
    制备和贮存
    溶解方法
    Reconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
    声明 :本官网所有报价均为常温或者蓝冰运输价格,如有产品需要干冰运输,需另外加收干冰运输费。
    货号:
    207-IL-005/CF
    一键复制
    询价
    5ug
    10UG
    25ug
    50UG
    200ug
    选择数量
    当前规格1件起购 
    配送至
    预计2-3周送达,快递: 免运费,若需干冰额外收费